It was originally hoped that the presence of mutations in KRAS and other related genes would provide an easy answer as to whether to administer anti-EGFR antibody therapy to a given metastatic colorectal cancer patient. However, in nature nothing is simple, and there are a number of issues that practicing clinicians should be made aware of.
|Original language||English (US)|
|Journal||ONCOLOGY (United States)|
|State||Published - Feb 15 2014|
ASJC Scopus subject areas
- Cancer Research